Results 111 to 120 of about 3,776 (143)

Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial. [PDF]

J Immunother Cancer, 2023
Chesney JA, Puzanov I, Collichio FA, Singh P, Milhem MM, Glaspy J, Hamid O, Ross M, Friedlander P, Garbe C, Logan T, Hauschild A, Lebbé C, Joshi H, Snyder W, Mehnert JM.   +15 more
europepmc   +1 more source

Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with advanced HER2-negative breast cancer. [PDF]

NPJ Breast Cancer
Huppert LA, Gliwa AS, Tait M, Quintal L, Starzinski S, Cheung A, Moasser M, Majure M, Melisko M, Munster P, Rugo HS, Campbell M, Fong L, Chien AJ.   +13 more
europepmc   +1 more source

Durable Complete Remission With Combination of Stereotactic Body Radiation Therapy (SBRT) and Talimogene Laherparepvec (TVEC) Followed by Ipilimumab in Refractory Metastatic Melanoma. [PDF]

Cureus, 2022
Wolfe Z, Blackham A, McIntosh A, Miller A, Sheikh H, Nair S.   +5 more
europepmc   +1 more source

Talimogene laherparepvec (T-VEC) levinneisyysluokan IIIB-D/IVM1a melanooman hoidossa HUS Syöpäklinikalla

Melanooma on vakavin ihosyöpätyyppi, jonka kehittymiseen vaikuttaa eniten ympäristöstä tullut UV-säteily. Primäärin ihomelanooman ensisijainen hoitokeino on laaja resektio riittävin kudosmarginaalein. Edenneen tautimuodon hoitokeinoja ovat immunoterapia,
Halme, Juho
core  

Phase I study of intratumoral injection of talimogene laherparepvec for the treatment of advanced pancreatic cancer. [PDF]

Oncologist
Runcie K, Bracero Y, Samouha A, Manji G, Remotti HE, Gonda TA, Saenger Y.   +6 more
europepmc   +1 more source

Histopathological and immunological spectrum in response evaluation of talimogene laherparepvec treatment and correlation with durable response in patients with cutaneous melanoma. [PDF]

Melanoma Res, 2022
Mulder EEAP, Damman J, Verver D, van der Veldt AAM, Tas S, Khemai-Mehraban T, Heezen KC, Wouters RA, Verhoef C, Verjans GMGM, Langerak AW, Grünhagen DJ, Mooyaart AL.   +12 more
europepmc   +1 more source

A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer. [PDF]

Sci Rep, 2021
Kai M, Marx AN, Liu DD, Shen Y, Gao H, Reuben JM, Whitman G, Krishnamurthy S, Ross MI, Litton JK, Lim B, Ibrahim N, Kogawa T, Ueno NT.   +13 more
europepmc   +1 more source

Phase Ib/II trial of talimogene laherparepvec alone and with pembrolizumab in advanced solid tumors with liver metastases and hepatocellular carcinoma. [PDF]

Oncologist
Hecht JR, Oberoi A, Garralda Cabanas E, Jae Chon H, Digklia A, Rottey S, Martin Jimenez M, Chaney M, Hippenmeyer J, Lawrence T, Liu K, Hamidi A, Chesney J.   +12 more
europepmc   +1 more source

Combined Regional Approach of Talimogene laherparepvec and Radiotherapy in the Treatment of Advanced Melanoma. [PDF]

Cancers (Basel)
Tam A, Ladbury C, Kassardjian A, Modi B, McGee H, Melstrom L, Margolin K, Xing Y, Amini A.   +8 more
europepmc   +1 more source

Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial). [PDF]

Nat Cancer
Ressler JM, Plaschka M, Silmbrod R, Bachmayr V, Shaw LE, Silly T, Zila N, Stepan A, Kusienicka A, Tschandl P, Tittes J, Roka F, Haslik W, Petzelbauer P, Koenig F, Kunstfeld R, Farlik M, Halbritter F, Weninger W, Hoeller C.   +19 more
europepmc   +1 more source